Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid

David Grimwade, A. Rahman A. Jamal, Nicholas Goulden, Helena Kempski, Stefano Mastrangelo, Paul Veys

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Detection of residual disease after completion of therapy or following bone marrow transplantation (BMT) in patients with acute promyelocytic leukaemia (APL) predicts relapse and is associated with a poor prognosis. Here we describe the successful treatment of residual disease posttransplant in APL using prolonged all-trans retinoic acid (ATRA) therapy in two children in whom autologous BMT (ABMT) had been performed in second complete remission (CR). ATRA treatment was well tolerated and found to be beneficial despite its prior use as a component of the initial induction protocol. ATRA therapy post-transplant led to molecular remission as determined by fluorescence in situ hybridization (FISH) as well as reverse transcriptase-polymerase chain reaction (RT-PCR) analyses and remission now exceeds 3.5 years in both patients. Overall, this study not only demonstrates that ATRA may successfully salvage APL patients with residual disease post-transplant, but also suggests a potential role for retinoids post-consolidation as a means of eliminating residual disease which could be beneficial even in patients previously exposed to ATRA as a component of the induction protocol.

Original languageEnglish
Pages (from-to)559-562
Number of pages4
JournalBritish Journal of Haematology
Volume103
Issue number2
DOIs
Publication statusPublished - 1998

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Bone Marrow Transplantation
Transplants
Therapeutics
Autologous Transplantation
Retinoids
Reverse Transcriptase Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Recurrence

Keywords

  • ABMT
  • APL
  • ATRA
  • FISH
  • MRD monitoring

ASJC Scopus subject areas

  • Hematology

Cite this

Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid. / Grimwade, David; A. Jamal, A. Rahman; Goulden, Nicholas; Kempski, Helena; Mastrangelo, Stefano; Veys, Paul.

In: British Journal of Haematology, Vol. 103, No. 2, 1998, p. 559-562.

Research output: Contribution to journalArticle

Grimwade, David ; A. Jamal, A. Rahman ; Goulden, Nicholas ; Kempski, Helena ; Mastrangelo, Stefano ; Veys, Paul. / Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid. In: British Journal of Haematology. 1998 ; Vol. 103, No. 2. pp. 559-562.
@article{a4204ad2f1b746fdba7f0f6003b36a1b,
title = "Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid",
abstract = "Detection of residual disease after completion of therapy or following bone marrow transplantation (BMT) in patients with acute promyelocytic leukaemia (APL) predicts relapse and is associated with a poor prognosis. Here we describe the successful treatment of residual disease posttransplant in APL using prolonged all-trans retinoic acid (ATRA) therapy in two children in whom autologous BMT (ABMT) had been performed in second complete remission (CR). ATRA treatment was well tolerated and found to be beneficial despite its prior use as a component of the initial induction protocol. ATRA therapy post-transplant led to molecular remission as determined by fluorescence in situ hybridization (FISH) as well as reverse transcriptase-polymerase chain reaction (RT-PCR) analyses and remission now exceeds 3.5 years in both patients. Overall, this study not only demonstrates that ATRA may successfully salvage APL patients with residual disease post-transplant, but also suggests a potential role for retinoids post-consolidation as a means of eliminating residual disease which could be beneficial even in patients previously exposed to ATRA as a component of the induction protocol.",
keywords = "ABMT, APL, ATRA, FISH, MRD monitoring",
author = "David Grimwade and {A. Jamal}, {A. Rahman} and Nicholas Goulden and Helena Kempski and Stefano Mastrangelo and Paul Veys",
year = "1998",
doi = "10.1046/j.1365-2141.1998.01008.x",
language = "English",
volume = "103",
pages = "559--562",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid

AU - Grimwade, David

AU - A. Jamal, A. Rahman

AU - Goulden, Nicholas

AU - Kempski, Helena

AU - Mastrangelo, Stefano

AU - Veys, Paul

PY - 1998

Y1 - 1998

N2 - Detection of residual disease after completion of therapy or following bone marrow transplantation (BMT) in patients with acute promyelocytic leukaemia (APL) predicts relapse and is associated with a poor prognosis. Here we describe the successful treatment of residual disease posttransplant in APL using prolonged all-trans retinoic acid (ATRA) therapy in two children in whom autologous BMT (ABMT) had been performed in second complete remission (CR). ATRA treatment was well tolerated and found to be beneficial despite its prior use as a component of the initial induction protocol. ATRA therapy post-transplant led to molecular remission as determined by fluorescence in situ hybridization (FISH) as well as reverse transcriptase-polymerase chain reaction (RT-PCR) analyses and remission now exceeds 3.5 years in both patients. Overall, this study not only demonstrates that ATRA may successfully salvage APL patients with residual disease post-transplant, but also suggests a potential role for retinoids post-consolidation as a means of eliminating residual disease which could be beneficial even in patients previously exposed to ATRA as a component of the induction protocol.

AB - Detection of residual disease after completion of therapy or following bone marrow transplantation (BMT) in patients with acute promyelocytic leukaemia (APL) predicts relapse and is associated with a poor prognosis. Here we describe the successful treatment of residual disease posttransplant in APL using prolonged all-trans retinoic acid (ATRA) therapy in two children in whom autologous BMT (ABMT) had been performed in second complete remission (CR). ATRA treatment was well tolerated and found to be beneficial despite its prior use as a component of the initial induction protocol. ATRA therapy post-transplant led to molecular remission as determined by fluorescence in situ hybridization (FISH) as well as reverse transcriptase-polymerase chain reaction (RT-PCR) analyses and remission now exceeds 3.5 years in both patients. Overall, this study not only demonstrates that ATRA may successfully salvage APL patients with residual disease post-transplant, but also suggests a potential role for retinoids post-consolidation as a means of eliminating residual disease which could be beneficial even in patients previously exposed to ATRA as a component of the induction protocol.

KW - ABMT

KW - APL

KW - ATRA

KW - FISH

KW - MRD monitoring

UR - http://www.scopus.com/inward/record.url?scp=0031784889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031784889&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1998.01008.x

DO - 10.1046/j.1365-2141.1998.01008.x

M3 - Article

VL - 103

SP - 559

EP - 562

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -